Ivosidenib - Wikipedia
Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.
TIBSOVO® (ivosidenib tablets)
Differentiation syndrome is a common condition that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO.
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma
On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic...
FDA approves ivosidenib for myelodysplastic syndromes - U.S.
On October 24, 2023, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS)...
Ivosidenib Uses, Side Effects & Warnings - Drugs.com
Aug 22, 2024 · What is ivosidenib? Ivosidenib targets a specific gene mutation called IDH1, which can affect your bone marrow. IDH1 mutation prevents young blood cells from developing into …
Tibsovo: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 20, 2018 · Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called the isocitrate dehydrogenase-1 (IDH1) mutation, which can affect your bone marrow.
Ivosidenib (oral route) - Mayo Clinic
Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy).
Ivosidenib - NCI - National Cancer Institute
Ivosidenib works by blocking an abnormal enzyme that some cancer cells with specific changes in the IDH-1 gene make. Blocking the abnormal enzyme may make cancer cells differentiate to become more like normal cells and grow more slowly.
Ivosidenib Tablets: Uses & Side Effects - Cleveland Clinic
IVOSIDENIB (EYE voe SID e nib) targets proteins in cancer cells and stops the cancer cells from growing. It treats acute myelogenous leukemia and cholangiocarcinoma.
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as...